Independent analysis of cash-pay longevity, for the operators building, investors evaluating, and biohackers buying. We synthesize 5,734 podcast operators, 141,000 investor notes, and 17 years of family lab data into a bi-weekly brief. Faceless. Every claim sourced.
Compounded is a faceless analyst publication. There is no founder, no headshot, no LinkedIn - by design. The value here is not personality. It is the substrate: a 5,734-episode operator-podcast corpus, four years of buy-side deal notes, and one family’s 17-year biomarker record, read in parallel.
Anonymity buys independence. We cover the operators and processors who serve this market without owing any of them coverage in return. Every claim is sourced - FDA letter, podcast timestamp, SEC filing, scraped data point. If you want a name attached to a take, read someone else.
What you can expect: bi-weekly long-form, free, no tracking pixels, no sponsored placements in the body of the analysis. Not investment advice. Not medical advice.
Every claim in Compounded is sourced. FDA letters by URL, SEC filings by docket number, podcast claims by episode and timestamp, vendor relationships by press release or public client list. If we cannot link it, we do not publish it. That is the audit trail, and it is how an anonymous publication earns trust.
If we name an operator in a piece, they get 72 hours to respond before we publish. Their response, if any, gets included. That is the cheapest insurance against bad faith and the easiest way to keep operators talking to us over time.
When we get something wrong, we say so. Updated piece live within 24 hours with a dated note at the top, and a line in the next issue. Trust comes from visible self-correction, not from pretending to a perfect record nobody would believe.
What we don't do: insider gossip. Unverified rumors. Deal-flow scoops. Hit pieces on operators trying their best. We're not a Twitter-thread account. We're an analyst publication, and the two are different products with different obligations.
We are open about what we don't know. Every piece ends with a list of the limits of our knowledge. If you spot an error: corrections@compounded.health. If you have material that would sharpen an upcoming piece: tips@compounded.health. Anonymous, encrypted on request.
You're launching a longevity, peptide, hormone, or cash-pay clinic. You need to know what stack your competitors are using, which processors and pharmacies will actually serve you, and what's about to break or open in regulation. Our Stack Maps and Regulatory Briefs are for you.
You evaluate cash-pay healthcare companies for a fund, a family office, or your own checkbook. You need pattern-recognition across the vertical, comparable-company depth, and a sober read on regulatory risk that isn't either cheerleading or hit-piece journalism. Our Pattern Memos and Corpus Quarterlies are for you.
You take peptides or GLP-1s or hormones. You want to understand what you're actually buying, who's actually behind it, and how the regulatory ground is shifting under your supplier. We translate the operator and regulatory side into something you can use without becoming a compounding-pharmacy lawyer. Our Regulatory Briefs and N=1 Lab Reports are for you.
How operators are actually built. Vendors, high-risk processors, LegitScript posture, fulfillment partners, ad accounts, patient-data tooling - drawn from public sources and cross-referenced against the corpus. If you're thinking about launching a clinic in this space, this is the layer-by-layer view of how the existing ones did it.
Blood panels, Whoop traces, continuous glucose, sleep architecture - run on real protocols, anonymized per a published rule set. Honest about what moved and what didn't. If you take peptides or GLP-1s or hormones yourself, this is the long-form data your operator's marketing won't show you.
What N podcast operators said about X this quarter. Drawn from a 5,734-episode FTS index plus 141K buy-side deal notes. Signal that nobody listens to all of, in one read. If you're investing in the vertical or competing inside it, this is the cross-operator pattern recognition that no single interview gives you.
FDA warning letters, state med-board moves, processor BRAM updates, VIRP timelines. What changed, who it hits first, and the second-order effects through the supply chain. If your operator or your supplier just got hit, this is the brief that tells you whether it matters for you.
How today's longevity market resembles historical analogs. Dot-com infrastructure, early DTC, fintech rails '14-'18. Pattern matching from inside the deal-flow corpus. If you're an investor or strategic operator trying to figure out where this market goes next, this is the historical playbook.
The whole industry is betting on a July FDA peptide vote. Almost nobody is asking what a "yes" would actually be worth. The base rate, the three machines, and why July 23 changes far less, far slower, than the people pricing it believe.Source: Federal Register + FDA dockets + the operator corpus. 16 citations.
A $6M seed just validated a new architecture for selling peptides: a five-question "application," one clinician on retainer, a partnered pharmacy, and a Stripe account. We map the whole stack, what it covers legally, and the one product line that breaks it.Source: public-source intake teardown + the regulatory map.
The full-telehealth example, by contrast to the Protocole wrapper. Vendor stack, high-risk processing, compliance posture, pharmacy partner, patient-data tooling. The public-source map of an operator most of this audience has heard of.Source: competitive intel work + corpus cross-reference.
Concierge clinics are prescribing semaglutide at a fraction of the label dose for people who aren't obese. The AACE legitimized the conversation this year. We pull the actual evidence, the safety gaps, and where this is heading before the PCAC vote.Source: corpus synthesis + clinical literature.
The piece that holds Issue 001 to account. Scenario by scenario, what the committee recommended, where we were right, where we were wrong, and what every operator archetype does with the result.Source: PCAC meeting record + staff briefing documents.
The industry treats July 23 like it's a single decision. It's three, and they run on different fuel: a political referral that already happened, a scientific vote against a committee that has approved zero of its first twelve reviews, and a rulemaking process that has historically taken four years or never finished at all. Even a clean "yes" doesn't make one peptide legal in 2026.